Cargando…

Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited o...

Descripción completa

Detalles Bibliográficos
Autores principales: Loghavi, Sanam, Alayed, Khaled, Aladily, Tariq N., Zuo, Zhuang, Ng, Siok-Bian, Tang, Guilin, Hu, Shimin, Yin, C. Cameron, Miranda, Roberto N., Medeiros, L. Jeffrey, Khoury, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472407/
https://www.ncbi.nlm.nih.gov/pubmed/26055271
http://dx.doi.org/10.1186/s13045-015-0163-z
_version_ 1782377052233531392
author Loghavi, Sanam
Alayed, Khaled
Aladily, Tariq N.
Zuo, Zhuang
Ng, Siok-Bian
Tang, Guilin
Hu, Shimin
Yin, C. Cameron
Miranda, Roberto N.
Medeiros, L. Jeffrey
Khoury, Joseph D.
author_facet Loghavi, Sanam
Alayed, Khaled
Aladily, Tariq N.
Zuo, Zhuang
Ng, Siok-Bian
Tang, Guilin
Hu, Shimin
Yin, C. Cameron
Miranda, Roberto N.
Medeiros, L. Jeffrey
Khoury, Joseph D.
author_sort Loghavi, Sanam
collection PubMed
description BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. PATIENTS AND METHODS: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. RESULTS: Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013), stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008). CONCLUSIONS: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0163-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4472407
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44724072015-06-20 Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients Loghavi, Sanam Alayed, Khaled Aladily, Tariq N. Zuo, Zhuang Ng, Siok-Bian Tang, Guilin Hu, Shimin Yin, C. Cameron Miranda, Roberto N. Medeiros, L. Jeffrey Khoury, Joseph D. J Hematol Oncol Research Article BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. PATIENTS AND METHODS: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. RESULTS: Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013), stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008). CONCLUSIONS: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0163-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-10 /pmc/articles/PMC4472407/ /pubmed/26055271 http://dx.doi.org/10.1186/s13045-015-0163-z Text en © Loghavi et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Loghavi, Sanam
Alayed, Khaled
Aladily, Tariq N.
Zuo, Zhuang
Ng, Siok-Bian
Tang, Guilin
Hu, Shimin
Yin, C. Cameron
Miranda, Roberto N.
Medeiros, L. Jeffrey
Khoury, Joseph D.
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title_full Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title_fullStr Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title_full_unstemmed Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title_short Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
title_sort stage, age, and ebv status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472407/
https://www.ncbi.nlm.nih.gov/pubmed/26055271
http://dx.doi.org/10.1186/s13045-015-0163-z
work_keys_str_mv AT loghavisanam stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT alayedkhaled stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT aladilytariqn stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT zuozhuang stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT ngsiokbian stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT tangguilin stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT hushimin stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT yinccameron stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT mirandaroberton stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT medeirosljeffrey stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients
AT khouryjosephd stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients